31 May 2017

Scancell Holdings PLC

Scancell Holdings PLC (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, has conducted a secondary placing of shares to raise £5 million. 

The proceeds will be used to support the company's clinical development pipeline, in particular to initiate clinical development of the first product from the Moditope(R) platform, Modi-1, and to continue to support the pipeline arising from the ImmunoBody(R) platform.  LGB Investments worked closely with the company's broker, Panmure Gordon, to introduce investors to the transaction.

Recent Articles

28 April 2021

The start of a supercycle?

With the UK government last year announcing that green hydrogen was to be central to the country’s ‘green industrial revolution' and the EU’s hydrogen roadmap forecasting €500bn being invested in the transition to a hydrogen-based economy by 2050, Read more

News & Insights

26 April 2021

Time Finance - Latest Issue

We are pleased to announce the successful completion of a £2 million note issuance under the Time Finance plc (formerly 1pm plc) MTN programme. 

Read more

Deals

20 April 2021

Market Commentary - Q1 2021

Q1 2021 was marked in the UK, and the US which continues to set the tone for world markets, by cautious optimism that the vaccine rollout will work, and that economies will restart. Read more

News & Insights